LETYBO
Growthletibotulinumtoxina-wlbg
BLAINTRAMUSCULARPOWDER, FOR SOLUTION
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LETYBO (letibotulinumtoxina-wlbg) is acetylcholine release inhibitors [moa]. First approved in 2024.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LETYBO (letibotulinumtoxina-wlbg) is a novel acetylcholine release inhibitor approved via BLA on February 29, 2024. It is administered intramuscularly as a powder for solution reconstitution. The drug mechanism targets neuromuscular junction function by inhibiting acetylcholine release, positioning it as a potential alternative in the botulinum toxin class.
Growth
Early-stage product in growth phase with competitive pressure at 30%; commercial team likely focused on market education and physician adoption.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LETYBO is a newly approved product in active growth phase, offering career opportunities in market launch execution, physician engagement, and early post-market safety monitoring. Current job posting volume is zero, but expected to increase as commercial infrastructure scales; roles will emphasize differentiation messaging against established competitors in the acetylcholine release inhibitor space.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.